J
J. Donald Easton
Researcher at University of California, San Francisco
Publications - 113
Citations - 22677
J. Donald Easton is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Stroke & Aspirin. The author has an hindex of 42, co-authored 104 publications receiving 20175 citations. Previous affiliations of J. Donald Easton include Brown University & Stanford University.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
Renato D. Lopes,Sana M. Al-Khatib,Lars Wallentin,Hongqiu Yang,Jack Ansell,M. Cecilia Bahit,Raffaele De Caterina,Paul Dorian,J. Donald Easton,Çetin Erol,Justin A. Ezekowitz,Bernard J. Gersh,Christopher B. Granger,Stefan H. Hohnloser,John D. Horowitz,Elaine M. Hylek,John J.V. McMurray,Puneet Mohan,Dragos Vinereanu,John H. Alexander +19 more
TL;DR: Apixaban significantly reduced stroke or systemic embolism with no evidence of a differential effect by risk of stroke, and patients who received apixaban had lower rates of major bleeding than did those who received warfarin.
Journal ArticleDOI
Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.
Pierre Amarenco,Gregory W. Albers,Hans Denison,J. Donald Easton,Scott R. Evans,Peter Held,Michael D. Hill,Jenny Jonasson,Scott E. Kasner,Per Ladenvall,Kazuo Minematsu,Carlos A. Molina,Yongjun Wang,K.S. Lawrence Wong,S. Claiborne Johnston +14 more
TL;DR: Ticagrelor was superior to aspirin at preventing stroke, myocardial infarction, or death at 90 days in patients with acute ischaemic stroke or transient ischaemia attack when associated with ipsilateral atherosclerotic stenosis.
Journal ArticleDOI
Design of Randomized, double‐blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE‐SPECT ESUS)
Hans-Christoph Diener,J. Donald Easton,Christopher B. Granger,Lisa Cronin,Christine Duffy,Daniel Cotton,Martina Brueckmann,Martina Brueckmann,Ralph L. Sacco +8 more
TL;DR: Whether anticoagulation with dabigatran is more effective than acetylsalicylic acid, and acceptably safe, is determined as part of the RE-SPECT ESUS trial.
Journal ArticleDOI
Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.
S. Claiborne Johnston,J. Donald Easton,Mary Farrant,William G. Barsan,Holly Battenhouse,Robin Conwit,Catherine Dillon,Jordan J. Elm,Anne S. Lindblad,Lewis B. Morgenstern,Sharon N. Poisson,Yuko Y. Palesch +11 more
TL;DR: This trial expects to determine whether more aggressive antithrombotic therapy with clopidogrel plus aspirin, initiated acutely, is more effective than aspirin alone.
Journal ArticleDOI
Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials
Yuesong Pan,Jordan J. Elm,Hao Li,J. Donald Easton,Yilong Wang,Mary Farrant,Xia Meng,Anthony S. Kim,Xingquan Zhao,William J. Meurer,Liping Liu,Dennis Dietrich,Yongjun Wang,S. Claiborne Johnston +13 more
TL;DR: The benefit of dual antiplatelet therapy appeared to be confined to the first 21 days after minor ischemic stroke or high-risk TIA, and no evidence of heterogeneity of treatment outcome across trials or prespecified subgroups was observed.